Steglujan®(ertugliflozin / sitagliptin) | Invokamet ®(metformin hydrochloride) |
---|---|
Prescription Only | Prescription Only |
Dosage & Administration | |
Administration | |
Dosing | |
Latin Shorthand | |
Financial Assistance | |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $0. Learn more. |
Annual Cap | |
$583 per fill . Learn more. | $3,000 and $200 per month. Learn more. |
Assistance Expiration | |
12 uses. Learn more. | Calendar year. Learn more. |
Generics | |
No lower-cost generic available | No lower-cost generic available |
Physician Advisory | |
Adverse Reactions | |
Most common adverse reactions associated with ertugliflozin
(incidence ≥5%): female genital mycotic infections.
Most common adverse reactions associated with sitagliptin
(incidence ≥5%): upper respiratory tract infection, nasopharyngitis
and headache. In the add-on to sulfonylurea and add-on to insulin
studies, hypoglycemia was also more commonly reported in patients
treated with sitagliptin compared to placebo.. Learn more. | Most common adverse reactions associated with canagliflozin (5% or
greater incidence): female genital mycotic infections, urinary tract
infection, and increased urination.
Most common adverse reactions associated with metformin HCl (5% or
greater incidence) are diarrhea, nausea, vomiting, flatulence, asthenia,
indigestion, abdominal discomfort, and headache. . Learn more. |
Mechanism of Actions (MoA) | |
SGLT2 Inhibitors. Learn more. | SGLT2 Inhibitors. Learn more. |
Special Populations | |